Methotrexate Pfizer Healthcare Ireland

Methotrexate, the active ingredient in Methotrexate Pfizer Healthcare Ireland, is an antimetabolite (folate antagonist) presented as a sterile injectable for intra‑arterial, intramuscular and intravenous use. It is employed to treat autoimmune disorders and several types of cancer in adult and pediatric patients. GNH USA supplies Methotrexate Pfizer Healthcare Ireland as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Methotrexate is used across a range of autoimmune and oncologic disease pathways. - Rheumatoid arthritis: reduces disease activity and joint inflammation. - Psoriasis: decreases skin plaque formation and severity. - Acute lymphoblastic leukemia: interferes with malignant cell proliferation. - Non‑Hodgkin lymphoma: induces tumor cell death. - Breast cancer: inhibits tumor growth as part of combination regimens. - Osteosarcoma: limits bone tumor progression.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea or vomiting - Fatigue or malaise - Oral mucosal ulceration - Mild elevation of liver enzymes - Transient low white blood cell counts - Mild alopecia

Serious or Rare Side Effects: - Severe hepatic toxicity or fibrosis - Pulmonary fibrosis or interstitial pneumonitis - Life‑threatening bone marrow suppression - Acute renal failure - Severe infection due to immunosuppression - Anaphylactic or severe hypersensitivity reactions

Methotrexate requires careful monitoring and specific safety measures. - Pregnancy: contraindicated (Category X); avoid use in women of childbearing potential unless effective contraception is used. - Renal function: assess baseline and monitor renal parameters; dose adjustment may be needed. - Hepatic function: perform liver function tests regularly; discontinue if significant toxicity occurs. - Hematologic monitoring: conduct complete blood counts before each dose to detect marrow suppression. - Concomitant NSAIDs or nephrotoxic drugs: avoid or use with caution due to increased renal risk. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and direct sunlight.

Methotrexate interacts with several drug classes that may alter its safety or efficacy.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate toxicity. - Sulfonamide antibiotics (e.g., trimethoprim‑sulfamethoxazole): potentiate bone marrow suppression. - Live vaccines: risk of severe infection due to immunosuppression. - Other folate antagonists (e.g., pemetrexed): additive toxicity. - High‑dose aspirin: may impair renal clearance.

Moderate Interactions (Monitor Closely): - Azathioprine or cyclosporine: enhanced immunosuppressive effect. - Carbamazepine or phenytoin: may reduce methotrexate plasma levels. - Oral contraceptives: possible reduced efficacy; advise alternative contraception.